Therapeutic potential of targeting the receptor for advanced glycation end products (RAGE) by small molecule inhibitors

Receptor for advanced glycation end products (RAGE) is a 45 kDa transmembrane receptor of immunoglobulin family that can bind to various endogenous and exogenous ligands and initiate the inflammatory downstream signaling pathways. RAGE is involved in various disorders including cardiovascular and ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Harbinder, Agrawal, Devendra K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474610/
https://www.ncbi.nlm.nih.gov/pubmed/35781678
http://dx.doi.org/10.1002/ddr.21971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474610/
https://www.ncbi.nlm.nih.gov/pubmed/35781678
http://dx.doi.org/10.1002/ddr.21971

Ejemplares similares